Ayala Pharmaceuticals to Present at 2019 Ladenburg Thalmann Healthcare Conference

REHOVOT, Israel & WILMINGTON, Del., September 17, 2019 – (BUSINESS WIRE) – Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers, today announced that Roni Mamluk, Ph.D., Chief Executive Officer of Ayala, will present at the 2019 Ladenburg Thalmann Healthcare Conference on Tuesday, September 24, 2019 at 10:30am ET in New York, NY.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. Ayala is broadly developing its product candidates, AL101 and AL102, best-in-class gamma secretase inhibitors, with clinical and preclinical studies underway in both solid tumors (AL101) and hematologic malignancies (AL102). Ayala’s lead product candidate, AL101, is currently in phase 2 for adenoid cystic carcinoma patients with tumor bearing Notch activating mutations (ACCURACY).  For more information, visit www.ayalapharma.com

Contacts:

Investors

Julie Seidel
Stern Investor Relations, Inc.
212-362-1200
Julie.seidel@sternir.com

Ayala Pharmaceuticals:
+1-857-444-0553
info@ayalapharma.com

2019-10-28T10:24:26+00:00